Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study

被引：7

作者：

Gallipoli, Paolo ^{[1
]}

Shepherd, Pat ^{[2
]}

Irvine, David ^{[1
]}

Drummond, Mark ^{[3
]}

Holyoake, Tessa ^{[1
]}

机构：

[1] Univ Glasgow, Inst Canc Sci, Glasgow G12 0XB, Lanark, Scotland

[2] Western Gen Hosp, Dept Haematol, Edinburgh EH4 2XU, Midlothian, Scotland

[3] W Scotland Canc Ctr, Dept Haematol, Glasgow, Lanark, Scotland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2011年 / 155卷 / 01期

基金：

英国医学研究理事会;

关键词：

chronic; myeloid; leukaemia; tyrosine-kinases; inhibitors; FOLLOW-UP; IMATINIB; CRITERIA;

D O I：

10.1111/j.1365-2141.2011.08653.x

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：128 / 130

页数：4

共 10 条

[1]

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[2]

Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention [J].

Breccia, Massimo ;

Orlandi, Sonia M. ;

Latagliata, Roberto ;

Grammatico, Sara ;

Diverio, Daniela ;

Mancini, Marco ;

Loglisci, Giuseppina ;

Salaroli, Adriano ;

Federico, Vincenzo ;

Santopietro, Michelina ;

Alimena, Giuliana .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (01) :119-121

[3]

Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis [J].

de Lavallade, Hugues ;

Apperley, Jane F. ;

Khorashad, Jamshid S. ;

Milojkovic, Dragana ;

Reid, Alistair G. ;

Bua, Marco ;

Szydlo, Richard ;

Olavarria, Eduardo ;

Kaeda, Jaspal ;

Goldman, John M. ;

Marin, David .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3358-3363

[4]

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[5]

Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed [J].

Eliasson, Lina ;

Clifford, Sarah ;

Barber, Nick ;

Marin, David .

LEUKEMIA RESEARCH, 2011, 35 (05) :626-630

[6]

Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia Resistant to Imatinib at a Dose of 400 to 600 Milligrams Daily Two-Year Follow-Up of a Randomized Phase 2 Study (START-R) [J].

Kantarjian, Hagop ;

Pasquini, Ricardo ;

Levy, Vincent ;

Jootar, Saengsuree ;

Holowiecki, Jerzy ;

Hamerschlak, Nelson ;

Hughes, Timothy ;

Bleickardt, Eric ;

Dejardin, David ;

Cortes, Jorge ;

Shah, Neil P. .

CANCER, 2009, 115 (18) :4136-4147

[7]

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials [J].

Lucas, C. M. ;

Wang, L. ;

Austin, G. M. ;

Knight, K. ;

Watmough, S. J. ;

Shwe, K. H. ;

Dasgupta, R. ;

Butt, Nauman M. ;

Galvani, D. ;

Hoyle, C. F. ;

Seale, J. R. C. ;

Clark, R. E. .

LEUKEMIA, 2008, 22 (10) :1963-1966

[8]

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib [J].

Marin, David ;

Bazeos, Alexandra ;

Mahon, Francois-Xavier ;

Eliasson, Lina ;

Milojkovic, Dragana ;

Bua, Marco ;

Apperley, Jane F. ;

Szydlo, Richard ;

Desai, Ritti ;

Kozlowski, Kasia ;

Paliompeis, Christos ;

Latham, Victoria ;

Foroni, Letizia ;

Molimard, Mathieu ;

Reid, Alistair ;

Rezvani, Katy ;

de Lavallade, Hugues ;

Guallar, Cristina ;

Goldman, John ;

Khorashad, Jamshid S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) :2381-2388

[9]

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor [J].

Marin, David ;

Milojkovic, Dragana ;

Olavarria, Eduardo ;

Khorashad, Jamshid S. ;

de lavallade, Hugues ;

Reid, Alistair G. ;

Foroni, Letizia ;

Rezvani, Katayoun ;

Bua, Marco ;

Dazzi, Francesco ;

Pavlu, Jiri ;

Klammer, Matthias ;

Kaeda, Jaspal S. ;

Goldman, John M. ;

Apperley, Jane F. .

BLOOD, 2008, 112 (12) :4437-4444

[10]

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia [J].

Saglio, Giuseppe ;

Kim, Dong-Wook ;

Issaragrisil, Surapol ;

le Coutre, Philipp ;

Etienne, Gabriel ;

Lobo, Clarisse ;

Pasquini, Ricardo ;

Clark, Richard E. ;

Hochhaus, Andreas ;

Hughes, Timothy P. ;

Gallagher, Neil ;

Hoenekopp, Albert ;

Dong, Mei ;

Haque, Ariful ;

Larson, Richard A. ;

Kantarjian, Hagop M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24) :2251-2259

← 1 →